title: Transmission of symptomatic parvovirus B19 infection by clotting factor concentrate.
abstract: The risk of acquiring diseases from transfusion of blood and blood products is well recognized and the issue of parvovirus in haemophiliacs is not a new one. We report two patients with haemophilia acquiring iatrogenic parvovirus B19 infection, resulting in life-threatening sepsis in one, and immunocompetent adult. Over the last 10 years there has been great progress in manufacturing safer products with regard to enveloped viruses such as HIV, hepatitis B and C. A recent outbreak across Europe of hepatitis A in haemophiliacs treated with plasma-derived factor VII concentrates has made haemophilic treaters concerned about the known (parvovirus B19 and hepatitis A) and the unknown non-lipid enveloped viruses that may be contained in the clotting factor concentrates, because these are resistant to the existing viral inactivating techniques. The possibility of HIV itself mutating into a non-lipid enveloped virus emphasizes the need to seek and use safer products.
authors.affiliation: Haemophilia Centre and Haemostasis Unit, Royal Free Hospital, London, UK.
authors.forename: T T
authors.initials: TT
authors.lastname: Yee
authors.forename: B J
authors.initials: BJ
authors.lastname: Cohen
authors.forename: K J
authors.initials: KJ
authors.lastname: Pasi
authors.forename: C A
authors.initials: CA
authors.lastname: Lee
mesh_terms: D000328:Adult; D016913:Blood Component Transfusion / Q000009:adverse effects*; D016731:Erythema Infectiosum / Q000635:transmission*; D005164:Factor IX / Q000008:administration & dosage*; D005167:Factor VII / Q000008:administration & dosage*; D005260:Female; D006467:Hemophilia A / Q000150:complications; D006801:Humans; D008297:Male; D016732:Parvovirus B19, Human
chemical_list: D005167:Factor VII; D005164:Factor IX